- Our Doctors
- Dr Hannah Tharmalingam
Dr Hannah Tharmalingam
MA (Oxon) BMBCh MRCP FRCR MD (Res), Consultant Clinical Oncologist
Languages spoken
English
Expert in
Gynaecological and Urological cancers
Overview
Centres
Specialises in
Treatments
Dr. Hannah Tharmalingam trained in medicine at the University of Oxford, graduating with a First-Class Honours degree. She completed specialist training in Clinical Oncology in North London and was subsequently appointed as a consultant at Mount Vernon Cancer Centre (MVCC) in Northwood, specializing in gynaecological and urological cancers. Dr. Tharmalingam has extensive clinical experience in the multi-disciplinary management of patients with these cancers, including both systemic and radiation therapies, and she regularly utilizes MRI-based technology and advanced techniques such as stereotactic radiotherapy (SABR).
She has a specialist interest in HDR brachytherapy, having undertaken a Clinical Research Fellowship at The Christie Hospital, where she led two large multi-centre cohort trials on behalf of the National UK HDR prostate brachytherapy group. Dr. Tharmalingam is now a research-active clinician, serving as Principal Investigator on a number of trials. In 2021, she was awarded two charitable research grants totaling £200,000 to open the EMPIRIC trial at Mount Vernon Cancer Centre, where she is evaluating functional MRI and molecular biomarkers to derive personalized radiogenomic prognostic models for patients with cervix cancer.
In 2019, Dr. Tharmalingam was appointed through an election of UK oncologists into the role of Vice-President for the Faculty of Clinical Oncology of the Royal College of Radiologists, where she led the delivery of training and professional strategy at a national level. She now acts as a Clinical Advisor for Macmillan Cancer Support, one of the UK’s largest cancer charities.
.svg){kind=icon}
Career positions
Current position(s)
- Consultant Clinical Oncologist in gynaecological and urological malignancies, Mount Vernon Cancer Centre, Northwood, UK
Year qualified
2009
Expertise and interests
Research interests
- Functional MRI imaging
- Tumor hypoxia
- Radiogenomics
- Radiotherapy biomakers
Clinical interests
- Personalised radiotherapy
- Brachytheraphy
- Health equity
Professional memberships
- Royal College of Radiologists (RCR)
- European Society for Radiotherapy and Oncology (ESTRO)
- British Urology Group (BUG)
Publications & affiliations
- Abdul-Latif M, Tharmalingam H, Tsang Y, Hoskin PJ. Functional magnetic resonance imaging in cervical cancer diagnosis and treatment. Clin Oncol. 2023 Sep 35(9):598-610
- Tharmalingam H, Tsang Y, Alonzi R et al. Changes in magnetic resonance imaging radiomic features in response to androgen deprivation therapy in patients with intermediate- and high-risk prostate cancer. Clin Oncol. 2022 Jun 34(6):e246-e253
- Tsang Y, Tharmalingam H, Belessiotis K et al. Ultra- hypofractionated radiotherapy for low and intermediate risk prostate cancer: high dose-rate brachytherapy vs stereotactic ablative radiotherapy. Radiother Oncol. 2021 May 158:184-190
- Tharmalingam H, Tsang Y, Ostler P et al. Single dose high-dose rate (HDR) brachytherapy as monotherapy for localized prostate cancer: early results of a National UK cohort study. Radiother Oncol. 2020 Feb;143:95-100
- Tharmalingam H, Tsang Y, Choudhury A et al. External beam radiotherapy (EBRT) and high-dose rate (HDR) brachytherapy for intermediate and high-risk prostate cancer: the impact of EBRT volume. Int J Rad Onc Bio Phys. 2020 Mar 1;106(3):525-533